SAVA Cassava Sciences, Inc.Stock Price & Overview
$16.800.16 (+0.96%)4:00 PM 10/02/23
NASDAQ | $USD | Post-Market: $16.77 -0.03 (-0.18%) 7:52 PM
Charts
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close
Quant Ranking
Analysis
News
Latest Headlines
Ratings Summary
| Now | 6M ago | |
|---|---|---|
SA Analysts | Not CoveredRating: Not Covered | |
Wall Street | Not CoveredRating: Not Covered | |
Quant | Not CoveredRating: Not Covered | |
Ratings Summary
SA Analysts
Wall Street
Quant
| Now | 3M ago | 6M ago | |
|---|---|---|---|
Valuation | -Rating: Not Covered | ||
Growth | -Rating: Not Covered | ||
Profitability | -Rating: Not Covered | ||
Momentum | -Rating: Not Covered | ||
Revisions | -Rating: Not Covered | ||
See SAVA ratings with Premium.
Company Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Address
- 6801 N. Capital of Texas Hwy, Bldg 1
- Suite 300
- Austin, TX, 78731
- United States
Phone Number
512 501 2444
Website